KR102304828B1 - 뉴모리신 돌연변이체 및 그의 사용 방법 - Google Patents

뉴모리신 돌연변이체 및 그의 사용 방법 Download PDF

Info

Publication number
KR102304828B1
KR102304828B1 KR1020177016881A KR20177016881A KR102304828B1 KR 102304828 B1 KR102304828 B1 KR 102304828B1 KR 1020177016881 A KR1020177016881 A KR 1020177016881A KR 20177016881 A KR20177016881 A KR 20177016881A KR 102304828 B1 KR102304828 B1 KR 102304828B1
Authority
KR
South Korea
Prior art keywords
lys
ser
asn
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177016881A
Other languages
English (en)
Korean (ko)
Other versions
KR20170083635A (ko
Inventor
로드니 케이. 트웨텐
Original Assignee
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 filed Critical 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마
Publication of KR20170083635A publication Critical patent/KR20170083635A/ko
Application granted granted Critical
Publication of KR102304828B1 publication Critical patent/KR102304828B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
KR1020177016881A 2014-11-21 2015-11-20 뉴모리신 돌연변이체 및 그의 사용 방법 Active KR102304828B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082848P 2014-11-21 2014-11-21
US62/082,848 2014-11-21
PCT/US2015/061859 WO2016081839A1 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20170083635A KR20170083635A (ko) 2017-07-18
KR102304828B1 true KR102304828B1 (ko) 2021-09-27

Family

ID=56014598

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177016881A Active KR102304828B1 (ko) 2014-11-21 2015-11-20 뉴모리신 돌연변이체 및 그의 사용 방법

Country Status (21)

Country Link
US (1) US10562941B2 (enExample)
EP (2) EP3220937B1 (enExample)
JP (1) JP6734274B2 (enExample)
KR (1) KR102304828B1 (enExample)
CN (1) CN107106635B (enExample)
AU (1) AU2015349787B2 (enExample)
CA (1) CA2968398A1 (enExample)
DK (1) DK3220937T3 (enExample)
ES (1) ES2993430T3 (enExample)
FI (1) FI3220937T3 (enExample)
HR (1) HRP20241627T1 (enExample)
HU (1) HUE069200T2 (enExample)
LT (1) LT3220937T (enExample)
MX (1) MX381872B (enExample)
PL (1) PL3220937T3 (enExample)
PT (1) PT3220937T (enExample)
RS (1) RS66221B1 (enExample)
SI (1) SI3220937T1 (enExample)
SM (1) SMT202400482T1 (enExample)
WO (1) WO2016081839A1 (enExample)
ZA (1) ZA201703881B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
EP3562838A2 (en) 2016-12-28 2019-11-06 Henriques Normark, Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
IL311239A (en) * 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN115927420A (zh) * 2022-05-27 2023-04-07 贵州省畜牧兽医研究所 一种溶血素重组表达及间接elisa检测方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341942A1 (en) 2008-12-24 2014-11-20 Eliud Oloo Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2221480A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
EP1098980B1 (en) 1998-07-22 2014-09-03 Stichting Dienst Landbouwkundig Onderzoek Streptococcus suis vaccines and diagnostic tests
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
JP2006506989A (ja) 2002-11-07 2006-03-02 シナジー アメリカ,インコーポレイテッド 肺炎球菌感染を治療または予防するための組成物および方法
WO2005076696A2 (en) 2004-02-13 2005-08-25 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US9370557B2 (en) 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
EP2386567B1 (en) * 2007-04-13 2014-10-29 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
WO2011075822A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
CL2010001216A1 (es) * 2010-11-08 2011-01-28 New Tech Copper S P A Sistema para confinar el espacio sobre el electrolito en una celda de electro obtencion y evacuar los aerosoles generados, que comprende un confinador insertado en cada anodo, con un par de proyecciones flexibles y un par de perfiles en angulo, y ductos longitudinales con perforaciones sobre el nivel del electrolito.
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
JP6397805B2 (ja) 2015-08-28 2018-09-26 東芝メモリ株式会社 半導体製造装置およびその運転方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341942A1 (en) 2008-12-24 2014-11-20 Eliud Oloo Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides

Also Published As

Publication number Publication date
RS66221B1 (sr) 2024-12-31
DK3220937T3 (da) 2024-12-02
JP6734274B2 (ja) 2020-08-05
CN107106635A (zh) 2017-08-29
JP2017536124A (ja) 2017-12-07
EP4501949A2 (en) 2025-02-05
WO2016081839A1 (en) 2016-05-26
BR112017010696A2 (pt) 2017-12-26
MX381872B (es) 2025-03-13
EP4501949A3 (en) 2025-04-30
LT3220937T (lt) 2024-12-27
FI3220937T3 (fi) 2024-11-29
AU2015349787A1 (en) 2017-06-22
HRP20241627T1 (hr) 2025-02-14
HUE069200T2 (hu) 2025-02-28
EP3220937A1 (en) 2017-09-27
EP3220937B1 (en) 2024-09-04
US10562941B2 (en) 2020-02-18
CA2968398A1 (en) 2016-05-26
SMT202400482T1 (it) 2025-01-14
PL3220937T3 (pl) 2025-01-27
SI3220937T1 (sl) 2025-03-31
US20180312552A1 (en) 2018-11-01
AU2015349787B2 (en) 2021-07-29
PT3220937T (pt) 2024-11-18
ZA201703881B (en) 2021-10-27
ES2993430T3 (en) 2024-12-30
EP3220937A4 (en) 2018-05-30
CN107106635B (zh) 2021-10-08
MX2017006625A (es) 2018-01-15
KR20170083635A (ko) 2017-07-18

Similar Documents

Publication Publication Date Title
CA2683748C (en) Mutants of cholesterol-dependent cytolysins and uses thereof
KR102304828B1 (ko) 뉴모리신 돌연변이체 및 그의 사용 방법
JP4689044B2 (ja) ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
KR100891398B1 (ko) 신규한 스트렙토코커스 항원
WO2000076540A2 (en) Streptococcus pneumoniae proteins and vaccines
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
JP4749641B2 (ja) ワクチン用の肺炎球菌タンパク質の相同体および断片
HK1237274A1 (en) Pneumolysin mutants and methods of use thereof
HK1237274B (en) Pneumolysin mutants and methods of use thereof
BR112017010696B1 (pt) Polipeptídeo de pneumolisina mutante purificada, composição imunogênica, métodos de preparo da dita composição imunogênica e uso do dito polipeptídeo para tratar, prevenir profilaticamente ou reduzir a ocorrência de uma condição, doença ou infecção causada por streptococcus pneumoniae

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170620

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201120

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20201120

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210311

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210817

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210915

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210916

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240729

Start annual number: 4

End annual number: 4